Lapatinib Ditosylate

Breast, Advance Directives, Postmenopause + 1 more

Treatment

6 FDA approvals

6 Active Studies for Lapatinib Ditosylate

What is Lapatinib Ditosylate

Lapatinib

The Generic name of this drug

Treatment Summary

Lapatinib is an anti-cancer medication developed by GlaxoSmithKline (GSK) to treat solid tumors such as breast and lung cancer. It was approved by the FDA in 2007 and is used in combination with the chemotherapy drug Capecitabine. Lapatinib works by blocking the activity of two proteins in the body, HER2/ERBB2 and HER1/EGFR/ERBB1. This prevents them from binding together, which helps stop the growth and spread of cancer cells.

Tykerb

is the brand name

image of different drug pills on a surface

Lapatinib Ditosylate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Tykerb

Lapatinib

2007

3

Approved as Treatment by the FDA

Lapatinib, also called Tykerb, is approved by the FDA for 6 uses which include refractory, metastatic Breast cancer and Metastatic Breast Cancer .

refractory, metastatic Breast cancer

Used to treat refractory, metastatic Breast cancer in combination with Capecitabine

Metastatic Breast Cancer

Used to treat Metastatic Breast Cancer in combination with Letrozole

Breast

Used to treat refractory, metastatic Breast cancer in combination with Capecitabine

Postmenopause

Used to treat Postmenopausal in combination with Letrozole

Metastatic Breast Cancer

Used to treat Metastatic Breast Cancer in combination with Letrozole

Advance Directives

Used to treat refractory, advanced Breast cancer in combination with Capecitabine

Effectiveness

How Lapatinib Ditosylate Affects Patients

Lapatinib is a medication used to treat certain types of cancer, such as breast and lung cancer. It inhibits the growth of cancer cells by blocking certain proteins known as kinases. Developed by GlaxoSmithKline, the FDA approved lapatinib for use in advanced metastatic breast cancer in combination with capecitabine chemotherapy on March 13, 2007.

How Lapatinib Ditosylate works in the body

Lapatinib is a drug that works to stop cancer cells from growing. It works by targeting the tyrosine kinase domains of the epidermal growth factor receptor and human epidermal growth factor receptor, which are both associated with cancer. Studies have shown that Lapatinib is effective in stopping tumor cell growth in laboratory and animal models, and that it can be used in combination with other cancer medications for an even greater effect. Lapatinib also works well against cancer cells that have become resistant to other treatments.

When to interrupt dosage

The suggested amount of Lapatinib Ditosylate is contingent upon the recognized disorder, including Advance Directives, Postmenopause and Metastatic Breast Cancer. The quantity of dosage shifts, as per the approach of administration (e.g. Tablet - Oral or Oral) featured in the table beneath.

Condition

Dosage

Administration

Breast

, 250.0 mg

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Advance Directives

, 250.0 mg

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Postmenopause

, 250.0 mg

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Metastatic Breast Cancer

, 250.0 mg

, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Warnings

There are 20 known major drug interactions with Lapatinib Ditosylate.

Common Lapatinib Ditosylate Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Lapatinib.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Lapatinib.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Lapatinib.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Lapatinib.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Lapatinib.

Lapatinib Ditosylate Toxicity & Overdose Risk

One patient who took 3,000 mg of lapatinib for 10 days had severe diarrhea and vomiting on the last day of treatment.

image of a doctor in a lab doing drug, clinical research

Lapatinib Ditosylate Novel Uses: Which Conditions Have a Clinical Trial Featuring Lapatinib Ditosylate?

78 active trials are currently in progress to assess the efficacy of Lapatinib Ditosylate in providing Advance Directives, Metastatic Breast Cancer and Breast related treatments.

Condition

Clinical Trials

Trial Phases

Postmenopause

5 Actively Recruiting

Phase 2, Not Applicable

Breast

0 Actively Recruiting

Advance Directives

0 Actively Recruiting

Metastatic Breast Cancer

1 Actively Recruiting

Phase 1, Phase 2

Lapatinib Ditosylate Reviews: What are patients saying about Lapatinib Ditosylate?

4

Patient Review

3/11/2011

Lapatinib Ditosylate for HER2 Positive Breast Cancer

Despite some initial setbacks with side effects, this drug was eventually able to be reduced to an effective dose. In combination with other drugs, it successfully shrank a mass to the point where it was no longer visible on an MRI within three months.

3.3

Patient Review

4/9/2010

Lapatinib Ditosylate for HER2 Positive Breast Cancer

I took this in conjunction with Capacitabine. The first course of Lapatinib for four weeks and Capacitabine for three weeks showed significant improvement, pain reduction, and visible decrease in symptoms. However, when I started the second round, sudden bubbles appeared all over my body--particularly on my hands and feet--along with edema. This led my doctor to stop the medication.

2.3

Patient Review

11/2/2010

Lapatinib Ditosylate for HER2 Positive Breast Cancer

I had diarrhea every day while taking this medication. It was given to me as part of a clinical trial for women with HER2+ node positive breast cancer (I was stage 3). I'm hopeful that it will help prevent recurrence.

1.7

Patient Review

3/24/2014

Lapatinib Ditosylate for Hormone Receptor Positive, HER2 Positive Metastatic Breast Cancer

My face and scalp started developing painful acne-like pimples within two days of taking this medication. Unfortunately, it did not work for me as intended; I had to resort to traditional chemotherapy eventually.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about lapatinib ditosylate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How does lapatinib work in breast cancer?

"Tykerb is a HER2 inhibitor targeted therapy that works against HER2-positive breast cancers by blocking certain proteins that can cause uncontrolled cell growth."

Answered by AI

What is lapatinib used for?

"Lapatinib is used in conjunction with capecitabine to treat a certain type of advanced breast cancer in patients who have already received treatment with other chemotherapy drugs."

Answered by AI

What kind of inhibitor is lapatinib?

"Lapatinib is a drug taken orally that targets two proteins, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2). These proteins are often overexpressed in cancer."

Answered by AI

Is lapatinib FDA approved?

"The US Food and Drug Administration has approved Tykerb, in combination with capecitabine, as a treatment for patients with advanced or metastatic breast cancer who have overexpressed HER2 and have received prior therapies including an anthracycline, a taxane, and trastuzumab."

Answered by AI

Clinical Trials for Lapatinib Ditosylate

Image of Don tyson Center for Agricultural Sciencers in Fayetteville, United States.

Protein and Exercise for Postmenopausal Women

Any Age
Female
Fayetteville, AR

The goal of this clinical trial is to learn if consuming a higher protein diet that includes one serving of beef each day, in combination with resistance exercise, improves wellbeing in postmenopausal women. It will also tell us about how higher protein intake changes body composition and blood values related to health. The main questions it aims to answer are: * Does higher protein intake combined with resistance training improve mood and sleep in postmenopausal women? * What other health benefits to postmenopausal women experience when the follow a higher protein diet and participate in resistance exercise? Researchers will compare three groups 1) postmenopausal women living their daily lives as usual, 2) postmenopausal women consuming a higher protein diet, and 2) postmenopausal women consuming a higher protein diet and participating in resistance training. Participants will: * Consume a higher protein diet for 16 weeks * Participate in an at-home resistance training for 16 weeks * Keep a diary of their food intake, sleep habits, and mood * Have health assessments every 4 weeks

Recruiting
Has No Placebo

Don tyson Center for Agricultural Sciencers (+1 Sites)

Jamie Baum

Image of The Buck Institute for Research on Aging in Novato, United States.

GLYLO Supplement for Postmenopausal Aging

45 - 65
Female
Novato, CA

The aim of this study is to assess the effectiveness of GLYLO, a dietary supplement, in postmenopausal women aged 45 to 65 who are overweight or obese and have elevated HbA1c levels. Specifically, the study seeks to evaluate whether GLYLO can reduce advanced glycation end products (AGEs) levels, which are harmful compounds formed when sugar attaches to proteins or fats in the body and can contribute to aging and disease. The primary outcome of the study is to determine if GLYLO reduces AGEs, enhances metabolic and hormonal health, and mitigates age-related functional decline. This study includes one screening visit and three testing visits over a 6-month period. After eligibility is confirmed, participants will be randomly assigned to one of two groups to take either GLYLO (two capsules daily) or a placebo at home for 24 weeks. Participants will provide blood samples at every visit. During the three testing visits, they will complete physical performance and cognitive function tests, provide both blood and urine samples, and fill out quality of life and 24-hour dietary intake questionnaires. The dietary intake questionnaires will be completed only twice i.e. at the baseline visit and again at the final 6-month visit.

Recruiting
Advanced

The Buck Institute for Research on Aging

Have you considered Lapatinib Ditosylate clinical trials?

We made a collection of clinical trials featuring Lapatinib Ditosylate, we think they might fit your search criteria.
Go to Trials